11/24
07:00 am
aqst
Aquestive Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference
Low
Report
Aquestive Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference
11/13
12:36 pm
aqst
Jim Cramer on Aquestive Therapeutics: “I Think It's a Very Interesting Spec” [Yahoo! Finance]
Low
Report
Jim Cramer on Aquestive Therapeutics: “I Think It's a Very Interesting Spec” [Yahoo! Finance]
11/9
08:43 am
aqst
Looking at the Narrative for Aquestive Therapeutics After Patent Wins and FDA Milestones [Yahoo! Finance]
Medium
Report
Looking at the Narrative for Aquestive Therapeutics After Patent Wins and FDA Milestones [Yahoo! Finance]
11/8
07:58 am
aqst
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Released Earnings Last Week And Analysts Lifted Their Price Target To US$10.10 [Yahoo! Finance]
Medium
Report
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Released Earnings Last Week And Analysts Lifted Their Price Target To US$10.10 [Yahoo! Finance]
11/7
08:07 am
aqst
Aquestive Therapeutics (NASDAQ:AQST) had its price target raised by analysts at Piper Sandler from $5.00 to $8.00. They now have an "overweight" rating on the stock.
Low
Report
Aquestive Therapeutics (NASDAQ:AQST) had its price target raised by analysts at Piper Sandler from $5.00 to $8.00. They now have an "overweight" rating on the stock.
11/5
04:01 pm
aqst
Aquestive Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
Low
Report
Aquestive Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
11/4
07:00 am
aqst
Aquestive Therapeutics Announces Leadership Expansion to Support Growth
Medium
Report
Aquestive Therapeutics Announces Leadership Expansion to Support Growth
11/3
07:00 am
aqst
Aquestive Therapeutics to Participate in a Fireside Chat Hosted by Piper Sandler
Medium
Report
Aquestive Therapeutics to Participate in a Fireside Chat Hosted by Piper Sandler
10/30
07:00 am
aqst
Aquestive Therapeutics to Attend 2025 ACAAI Annual Meeting
Low
Report
Aquestive Therapeutics to Attend 2025 ACAAI Annual Meeting
10/27
07:00 am
aqst
Aquestive Therapeutics to Report Third Quarter 2025 Financial Results and Recent Business Highlights on November 5 and Host Conference Call on November 6 at 8:00 a.m. ET
Low
Report
Aquestive Therapeutics to Report Third Quarter 2025 Financial Results and Recent Business Highlights on November 5 and Host Conference Call on November 6 at 8:00 a.m. ET
10/24
04:22 pm
aqst
What Recent Patent Extensions and FDA Progress Mean for Aquestive Therapeutics's Valuation [Yahoo! Finance]
Low
Report
What Recent Patent Extensions and FDA Progress Mean for Aquestive Therapeutics's Valuation [Yahoo! Finance]
10/21
07:27 am
aqst
Aquestive Therapeutics (NASDAQ:AQST) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
Medium
Report
Aquestive Therapeutics (NASDAQ:AQST) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
10/10
05:36 am
aqst
Watching the Narrative for Aquestive Therapeutics Shift After Key Anaphylm Milestones [Yahoo! Finance]
Low
Report
Watching the Narrative for Aquestive Therapeutics Shift After Key Anaphylm Milestones [Yahoo! Finance]
10/9
07:19 am
aqst
Aquestive Therapeutics (NASDAQ:AQST) had its "outperform" rating reaffirmed by analysts at Citigroup Inc..
Medium
Report
Aquestive Therapeutics (NASDAQ:AQST) had its "outperform" rating reaffirmed by analysts at Citigroup Inc..
10/9
07:02 am
aqst
Aquestive Therapeutics (NASDAQ:AQST) was given a new $12.00 price target on by analysts at JMP Securities.
Medium
Report
Aquestive Therapeutics (NASDAQ:AQST) was given a new $12.00 price target on by analysts at JMP Securities.
10/8
07:52 am
aqst
Aquestive Therapeutics Broadens Patent Estate for Anaphylm™ [Yahoo! Finance]
Low
Report
Aquestive Therapeutics Broadens Patent Estate for Anaphylm™ [Yahoo! Finance]
10/8
07:00 am
aqst
Aquestive Therapeutics Broadens Patent Estate for Anaphylm™
Low
Report
Aquestive Therapeutics Broadens Patent Estate for Anaphylm™
10/3
03:30 pm
aqst
Aquestive Therapeutics (NASDAQ:AQST) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Neutral
Report
Aquestive Therapeutics (NASDAQ:AQST) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
9/25
07:48 pm
aqst
We have a potential $1 billion blockbuster product on our hands: Aquestive Therapeutics CEO [CNBC]
Low
Report
We have a potential $1 billion blockbuster product on our hands: Aquestive Therapeutics CEO [CNBC]
9/24
08:13 am
aqst
A Look at Aquestive Therapeutics's Valuation Following Positive FDA Update on Anaphylm [Yahoo! Finance]
Low
Report
A Look at Aquestive Therapeutics's Valuation Following Positive FDA Update on Anaphylm [Yahoo! Finance]
9/22
06:45 am
aqst
Aquestive Therapeutics (AQST) Soars 14.8%: Is Further Upside Left in the Stock? [Yahoo! Finance]
Medium
Report
Aquestive Therapeutics (AQST) Soars 14.8%: Is Further Upside Left in the Stock? [Yahoo! Finance]
9/22
03:55 am
aqst
Jim Cramer on Aquestive Therapeutics: “I think it's Worth Taking a Chance On” [Yahoo! Finance]
Medium
Report
Jim Cramer on Aquestive Therapeutics: “I think it's Worth Taking a Chance On” [Yahoo! Finance]
9/21
07:23 am
aqst
Aquestive Therapeutics (AQST) Is Up 12.3% After FDA Waives Panel for Oral Epinephrine Application [Yahoo! Finance]
Medium
Report
Aquestive Therapeutics (AQST) Is Up 12.3% After FDA Waives Panel for Oral Epinephrine Application [Yahoo! Finance]
9/8
08:46 am
aqst
Aquestive Therapeutics (NASDAQ:AQST) had its price target raised by analysts at Oppenheimer Holdings, Inc. from $7.00 to $8.00. They now have an "outperform" rating on the stock.
Medium
Report
Aquestive Therapeutics (NASDAQ:AQST) had its price target raised by analysts at Oppenheimer Holdings, Inc. from $7.00 to $8.00. They now have an "outperform" rating on the stock.
9/6
08:45 am
aqst
Aquestive Therapeutics: Expect Its Torrid Pace To Relax (Rating Downgrade) [Seeking Alpha]
Medium
Report
Aquestive Therapeutics: Expect Its Torrid Pace To Relax (Rating Downgrade) [Seeking Alpha]